Cynapsus Therapeutics

    [td_text_with_title custom_title=”Company description”]Cynapsus is a specialty pharmaceutical company developing a convenient and easy-to-use sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s disease. More than 1 million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson’s disease. Parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and communicate.[/td_text_with_title]
    [td_text_with_title custom_title=”Latest post”]

    Dexxon buys into Cynapsus IPO

    Cynapsus Therapeutics, which is developing an easier-to-use formulation of apomorphine for Parkinson’s disease, raised $63 million by offering 4.5 million shares at $14. A filing late Wednesday afternoon showed that Dexxon, which is Cynapsus’ largest shareholder, would buy up to its pro rata shares of Cynapsus’ common shares in the offering. Cynapsus Therapeutics, which already […]